Eupraxia Pharmaceuticals Inc.

TSX:EPRX.TO

Biotechnology

Healthcare
$8.86 +2.49%

+$0.22 today

Market cap
$595.76M
Beta
1.48
P/E (TTM)
-8.6
EPS (TTM)
-$0.74
52W Low $5.82High $12.86

Volume 0.16M

Average 0.05M

EPRX.TO Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Eupraxia Pharmaceuticals Inc.TSX: EPRX.TO

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue growth accelerates

Q1 FY2026 cost of revenue of $88.67K rose 89.3% year over year, ahead of the +30.3% change in trailing-twelve-month cost of revenue. Sequentially, it rose 19.9% from the prior quarter. Over 3 fiscal years it compounded at +7.8% a year.

Context

  • Cost of revenue increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +89.3% holds above the trailing-twelve-month pace of +30.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$88.67K+19.9% QoQ
Last fiscal yearDec 2025
$241.88K+48.0% YoY
LTMMar 2026
$281.1K+30.3% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+89.3%——
1 year+48.0%——
3-year CAGR+7.8%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

Mixed currencies · from the income statement

Latest · FY2025
241.88K USD
Year-over-year change
+48.0%

Cost of Revenue vs competitors

How EPRX.TO compares with its peers on the latest reported figures

  • Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +30.3% is the 5th highest of 8, against a peer median of +32.6%.
  • Over three fiscal years its annual growth of +7.8% compares with a peer median of -1.1%.
EPRX.TO Competitors
Cost of Revenue for EPRX.TO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
OGI.TOOrganiGram Holdings Inc.LTM Mar 2026CA$282.6M CAD+116.3%—103.1%
WEED.TOCanopy Growth CorporationLTM Mar 2026CA$237.39M CAD+25.3%-20.7%76.4%
DR.TOMedical Facilities CorporationLTM Mar 2026$168.32M USD+61.4%+3.7%55.1%
TSND.TOTerrAscend Corp.LTM Mar 2026$128.47M USD-10.2%-13.4%49.1%
PRN.TOProfound Medical Corp.LTM Mar 2026$5.43M USD+43.5%+9.4%29.0%
FRX.TOFennec Pharmaceuticals Inc.LTM Mar 2026$3.99M USD+32.6%+252.4%7.8%
EPRX.TOEupraxia Pharmaceuticals Inc.LTM Mar 2026$281.1K USD+30.3%+7.8%—
HBP.TOHelix BioPharma Corp.LTM Apr 2026CA$5K CAD-37.5%-5.9%—
Peer median (excluding EPRX.TO) —+32.6%-1.1%52.1%

Competitors are the stored peer set for EPRX.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

Mixed currencies
Metric
FY2021
Dec 2021 · CAD
FY2022
Dec 2022 · CAD
FY2023
Dec 2023 · USD
FY2024
Dec 2024 · USD
FY2025
Dec 2025 · USD
Revenue00000
Cost of Revenue111.53K193.27K158.05K163.47K241.88K
Gross Profit(111.53K)(193.27K)(158.05K)(163.47K)(241.88K)
Gross Margin—————
Research & Development10.17M17.58M21M15.17M21.51M
Selling, General & Admin8.2M5.81M7.37M10.92M17.1M
Operating Expenses18.38M23.38M28.37M25.54M38.86M
Depreciation & Amortization111.53K193.27K158.05K163.47K241.88K
EBITDA(21.96M)(22.14M)(28.16M)(23.43M)(38.86M)
EBITDA Margin—————
Operating Income(18.47M)(23.58M)(27.78M)(25.71M)(39.11M)
Operating Margin—————
Interest Income65.73K569.32K876.96K1.1M1.44M
Interest Expense1.3M1.59M1.19M913.1K0
Other Income / Expenses(4.9M)(341.09K)(1.08M)1.2M(155.19K)
Income Before Tax(23.37M)(23.92M)(28.93M)(24.51M)(39.26M)
Pre-Tax Margin—————
Income Tax Expense00(67.51K)1.72K19.42K
Net Income(22.99M)(23.26M)(28.15M)(24.28M)(39.25M)
Net Margin—————
EPS (Basic)(1.61)(1.21)(1.19)(0.72)(1.05)
EPS (Diluted)(1.61)(1.21)(1.19)(0.72)(1.05)
Weighted Avg Shares14.24M19.29M24.15M33.93M39.96M
Weighted Avg Shares (Diluted)14.24M19.29M24.15M33.93M39.96M

Eupraxia Pharmaceuticals Inc.

TSX:EPRX.TO

Intrinsic Alpha fair value

Locked

Current Price

$8.86

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.